Turkish Journal of Internal Medicine

Turkish Journal of Internal Medicine

A case report of euglycemic ketoacidosis due to dapagliflozin treatment

Yazarlar: Murat ÇALAPKULU, Muhammed Erkam SENCAR, İlknur ÖZTÜRK ÜNSAL, Hayri BOSTAN, Erman ÇAKAL

Cilt 3 , Sayı Supplement 1 , 2021 , Sayfalar 85 - 86

Konular:Genel ve Dahili Tıp

DOI:10.46310/tjim.877156

Anahtar Kelimeler:Dapagliflozin,Sodium-glucose co-transporter 2 inhibitors,Euglycemic ketoacidosis

Özet: Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose. The Food and Drug Administration issued a warning in May 2015 notifying that patients using this class of anti-diabetic drugs may develop DKA. Risk factors for DKA development among patients who take SGLT-2 inhibitors include carbohydrate intake/starvation or acute illness. In the current report, we aimed to present a case of euglycemic DKA using dapagliflozin treatment.

ATIFLAR
Atıf Yapan Eserler
Henüz Atıf Yapılmamıştır
KAYNAK GÖSTER
BibTex
KOPYALA
@article{2021, title={A case report of euglycemic ketoacidosis due to dapagliflozin treatment}, volume={3}, number={85–86}, publisher={Turkish Journal of Internal Medicine}, author={Murat ÇALAPKULU,Muhammed Erkam SENCAR,İlknur ÖZTÜRK ÜNSAL,Hayri BOSTAN,Erman ÇAKAL}, year={2021} }
APA
KOPYALA
Murat ÇALAPKULU,Muhammed Erkam SENCAR,İlknur ÖZTÜRK ÜNSAL,Hayri BOSTAN,Erman ÇAKAL. (2021). A case report of euglycemic ketoacidosis due to dapagliflozin treatment (Vol. 3). Vol. 3. Turkish Journal of Internal Medicine.
MLA
KOPYALA
Murat ÇALAPKULU,Muhammed Erkam SENCAR,İlknur ÖZTÜRK ÜNSAL,Hayri BOSTAN,Erman ÇAKAL. A Case Report of Euglycemic Ketoacidosis Due to Dapagliflozin Treatment. no. 85–86, Turkish Journal of Internal Medicine, 2021.
Atıf Görüntüle
PDF Görüntüle
Kaynak Görüntüle
Paylaş
Dergi Bilgileri